Long-term follow-up evaluation of readmissions after ventricular assist device implantation: trends and outcomes
Frontiers in Cardiovascular Medicine · 27.01.2026 · 13
DOI: 10.3389/fcvm.2026.1634771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 27.01.2026. Verfasst von Mehmet Aksüt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Kosuyolu High Specialization Research and Training Hospital, Istanbul, Türkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
With the increasing utilization of left ventricular assist devices (LVADs) as a pivotal treatment option for end-stage heart failure, the rehospitalization of patients equipped with these devices has emerged as a significant issue impacting both quality of life and healthcare costs. This study evaluates readmission trends, predisposing factors, and their effects on survival over a long-term follow-up period for patients undergoing LVAD implantation.
Methods
The study included 141 patients who underwent LVAD implantation between 2015 and 2023 and were followed for a minimum of 12 months. We analyzed the reasons for readmission, trends related to the devices, and overall outcomes.
Results
The median duration of LVAD support was 49 months (IQR: 22–60). Overall, 102 patients (72.3%) experienced at least one readmission, with a median of two readmissions per patient (IQR: 0–3). Patients who were readmitted had a significantly higher body mass index (median 26.3 kg/m 2 vs. 23.4 kg/m 2 , p = 0.003). In the multivariable Cox regression analysis, right ventricular dysfunction was the only factor independently associated with hospital readmission (HR = 1.769, 95% CI: 1.097–2.854, p = 0.019). Other variables—including body mass index, reoperative surgery, male gender, and tricuspid valve intervention—were not significantly associated with readmission. The most frequent causes of readmission were wound or driveline infections (33.7%), arrhythmias (16.9%), and right ventricular failure (11.8%). Long-term survival did not differ significantly between readmitted and non-readmitted patients ( p = 0.335). Among device types, HeartMate III demonstrated the best survival outcomes [median 60 (40–60) months].
Conclusion
Although LVAD implantation substantially improves survival in advanced heart failure, hospital readmissions remain common throughout long-term follow-up. Right ventricular dysfunction represents a key determinant of readmission risk, highlighting the importance of optimized perioperative management and vigilant monitoring for right-sided failure. Preventive strategies aimed at early detection of RV dysfunction and driveline complications may further reduce rehospitalizations and improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Kosuyolu High Specialization Research and Training Hospital, Istanbul, Türkiye.
Zitieren
APA
Aksüt, M., Özgür, M. M., Hancer, H., Yigit, F., Güneş, A., Topcu, K., Gurel, B., Özer, T., Altaş, Ö., Sarıkaya, S., & Kırali, K. (2026). Long-term follow-up evaluation of readmissions after ventricular assist device implantation: trends and outcomes. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1634771
Vancouver
Aksüt M, Özgür MM, Hancer H, Yigit F, Güneş A, Topcu K, et al. Long-term follow-up evaluation of readmissions after ventricular assist device implantation: trends and outcomes. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1634771
BibTeX
@article{Akst2026,
author = {Aksüt, Mehmet and Özgür, Mustafa Mert and Hancer, Hakan and Yigit, Fatih and Güneş, Ayhan and Topcu, Kamile and Gurel, Barış and Özer, Tanıl and Altaş, Özge and Sarıkaya, Sabit and Kırali, Kaan},
title = {Long-term follow-up evaluation of readmissions after ventricular assist device implantation: trends and outcomes},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1634771}
}
EUVIMED